Open AccessDrug Resistance to EGFR Inhibitors in Lung Cancer
Author(s) -
Osamu Tetsu,
Matthew J. Hangauer,
Janyaporn Phuchareon,
David W. Eisele,
Frank McCormick
Publication year - 2016
Publication title -
chemotherapy
Language(s) - English
Resource type - Journals
eISSN - 1421-9794
pISSN - 0009-3157
DOI - 10.1159/000443368
Subject(s) - medicine , drug resistance , lung cancer , drug , acquired resistance , cancer , epidermal growth factor receptor , pharmacology , cancer research , oncology , biology , microbiology and biotechnology
The discovery of mutations in epidermal growth factor receptor (EGFR) has dramatically changed the treatment of patients with non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths worldwide. EGFR-targeted therapies show considerable promise, but drug resistance has become a substantial issue.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom